GT Biopharma, Inc. Leases Disclosure
Note 8 – Operating Leases
On November 19, 2021, the Company entered into a sublease with a third party for 4,500 square feet of office space located in Brisbane, California, with a commencement date of January 1, 2022 and maturing on June 30, 2024. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Rent expense is recognized on a straight-line basis over the lease term. As a result of this agreement, the Company recognized right-of-use (“ROU”) asset and liability of $247,294 pursuant to ASC 842, Lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.
On February 8, 2022, the Company entered another lease which will end on February 7, 2025. As a result, the Company recognized additional ROU asset and liability of $12,861.
As a result of these lease agreements, the Company recognized ROU asset and liability in the aggregate of $260,155.
The components of rent expense and supplemental cash flow information related to leases for the period are as follows:
December 31, 2022 | ||||
| Lease Costs (in thousands): | ||||
| Operating cash flows from operating leases | $ | 109 | ||
| Other Information | ||||
| Weighted-average remaining lease term (in years): | 1.75 | |||
| Weighted-average discount rate: | 10 | % | ||
The supplemental balance sheet information related to leases for the period is as follows:
December 31, 2022 | ||||
| Operating leases (in thousands) | ||||
| Long-term right-of-use assets, net | $ | 165 | ||
| Current portion of operating lease liabilities | $ | 110 | ||
| Non-current portion of operating lease liabilities | 64 | |||
| Total operating lease liabilities | $ | 174 | ||
Maturities of the Company’s lease liabilities are as follows (in thousands):
| Year ending | Amount | |||
| 2023 | $ | 122 | ||
| 2024 | 91 | |||
| 2025 | 1 | |||
| Total lease payments | 214 | |||
| Less: Imputed interest/present value discount | (40 | ) | ||
| Present value of lease liabilities | $ | 174 | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2022 | Mar 30, 2023 | Showing above |
| 2020 | Apr 16, 2021 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.